The potential benefits and risks of the use of dual antiplatelet therapy beyond 6months following sirolimus-eluting stent implantation for low-risk patients

Journal of Cardiology

Volumn 57, Issue 3, 2011, Pages 283-289

  Nakagawa, Takafumi ^a   Hiasa, Yoshikazu ^a   Hosokawa, Shinobu ^a   Minami, Tomoko ^a   Yano, Yudai ^a   Yoneda, Kohei ^a   Mizobe, Michiko ^a   Murakami, Naotsugu ^a   Tobetto, Yohei ^a   Chen, Hirotoshi ^a   Miyazaki, Shinichiro ^a   Mahara, Keitaro ^a   Ogura, Riyo ^a   Miyajima, Hitoshi ^a   Yuba, Kenichiro ^a   Takahashi, Takefumi ^a   Kishi, Koichi ^a   Ohtani, Ryuji ^a  

^a TOKUSHIMA RED CROSS HOSPITAL   (Japan)

Author keywords

Bleeding; Dual antiplatelet therapy; Optimal duration; Sirolimus eluting stent

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; RAPAMYCIN; TICLOPIDINE;

AGED; ANTICOAGULANT THERAPY; ANTIPLATELET THERAPY; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CORONARY STENT; DEATH; DRUG ELUTING STENT; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; STENT THROMBOSIS; SURVIVAL RATE; TREATMENT DURATION;

AGED; CEREBRAL HEMORRHAGE; CORONARY VESSELS; DIABETES COMPLICATIONS; DRUG-ELUTING STENTS; FEMALE; HEMORRHAGE; HUMANS; MALE; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PROSTHESIS IMPLANTATION; RETROSPECTIVE STUDIES; SIROLIMUS; THROMBOSIS; TIME FACTORS;

EID: 79954994017     PISSN: 09145087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jjcc.2011.02.005     Document Type: Article

References (15)

1. King S.B., Smith S.C., Hirshfield J.W., Jacobs A.K., Morrison D.A., Feldman T.E., Kern M.J., O'Neil W.W., Schaff H.V., Whitlow P.L., Williams D.O., Adams V.C., Anderson J.L., Biller C.E., Creager M.A., et al. 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of American Heart Association Task Force on practice guidelines. Circulation 2008, 117:261-295.
2. Steinhubl S.R., Berger P.B., Mann J.T., Fry E.T., DeLago A., Wilmer C., Topol E.J. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized control trial. JAMA 2002, 288:2411-2420. CREDO investigators.
3. Mehta S.R., Yusuf S., Peters R.J., Bertrand M.E., Lewis B.S., Natarajan M.K., Malmberg K., Rupprecht H.J., Zhao F., Chrolavicius S., Copland I., Fox K.A. Effect of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001, 358:527-533. for the clopidogrel in unstable angina to prevent recurrent events trial (CURE) investigators.
4. Lee S.W., Park S.W., Yun S.C., Kim Y.H., Park D.W., Kim W.J., Lee J.Y., Lee C.W., Hong M.K., Kim J.J., Park S.J. Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: drug-eluting stenting followed by cilostazol treatment reduces adverse serious cardiac events (DECREASE registry). Am Heart J 2010, 159:284-291.
5. Wiviott S.D., Antman E.M., Gibson C.M., Montalescot G., Riesmeyer J., Weerakkody G., Winters K.J., Warmke J.W., McCabe C.H., Braunwald E. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel thrombolysis in myocardial infarction 38 (TRITON-TIMI38). Am Heart J 2006, 152:627-635. for the TRITON-TIMI 38 investigators.
6. Eisenstein E.L., Anstrom K.J., Kong D.F., Shaw L.K., Tuttle R.H., Mark D.B., Kramer J.M., Harrington R.A., Matchar D.B., Kandzari D.E., Peterson E.D., Shulman K.A., Califf R.M. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007, 297:159-168.
7. Kimura T., Morimoto T., Nakagawa Y., Tamura T., Kadota K., Yasumoto H., Nishikawa H., Hiasa Y., Muramatsu T., Meguro T., Inoue N., Honda H., Hayashi Y., Miyazaki S., Oshima S., et al. Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation 2009, 119:987-995.
8. Hajai K.J., Shenoy C., Orshaw P., Boura J. Dual antiplatelet therapy for more than 12months after percutaneous coronary intervention: insights from the Guthrie PCI Registry. Heart 2009, 95:1579-1586.
9. Shin D.H., Chae I.H., Youn T.J., Cho S.I., Kwon D.A., Suh J.W., Chang H.J., Cho Y.S., Chung W.Y., Choi Y.J., Gwon H.C., Han K.R., Choi D.J. Reasonable duration of clopidogrel use after drug-eluting stent implantation in Korean patients. Am J Cardiol 2009, 104:1668-1673.
10. Petersen J.L., Baron J.J., Hammill B.G., Cziraky M.J., Anstrom K.J., Wahl P.M., Eisenstein E.L., Krucoff M.W., Califf R.M., Schulman K.A., Curtis L.H. Clopidgrel use and clinical events after drug-eluting stent implantation: findings from the HealthCore Integrated Research Database. Am Heart J 2010, 159:462-470.
11. Latib A., Morici N., Cosgrave J., Airoldi F., Godino C., Brambilla N., Chieffo A., Bonizzoni E., Carlino M., Bedogni F., Montorfano M., Sangiorgi G.M., Briguori C., Colombo A. Incidence of bleeding and compliance on prolonged dual antiplatelet therapy (aspirin+thienopyridine) following drug-eluting stent implantation. Am J Cardiol 2008, 102:1477-1481.
12. Fujimoto H., Ishimura R., Tao S., Ito S., Fujimoto Y., Ishiwata S., Yamaguchi T., Ohno M. Two cases of acute coronary syndrome that occurred by preoperative discontinuation of antiplatelet therapy in the chronic phase after stent implantation. J Cardiol 2009, 54:470-474.
13. Tsukahara K., Kimura K., Morita S., Ebina T., Kosuge M., Hibi K., Okuda J., Iwahashi N., Maejima N., Nakachi T., Otsuka F., Hashiba K., Tahara Y., Sugano T., Uemura S. Impact of high-responsiveness to dual antiplatelet therapy on bleeding complications in patients receiving drug-eluting stents. Circ J 2010, 74:679-685.
14. Uchida Y., Mori F., Ogawa H., Takagi A., Hagiwara N. Impact of anticoagulant therapy on prognosis after treatment with drug-eluting coronary stents. J Cardiol 2010, 55:362-369.
15. Hokimoto S., Matsui K., Oshima S., Noda K., Kaikita K., Sumida H., Sugiyama S., Ogawa H. Effect of gastric medicines on gastroduodenal injury in patients with stable angina during antiplatelet therapy. J Cardiol 2009, 54:71-75.